SCHEMBL3008698

SCHEMBL3008698

CCCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
NPSR1 Q6W5P4 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HSD11B1 P28845 1/20 0.45
LSS P48449 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ATM Q13315 1/20 0.43
THRB P10828 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
USP2 O75604 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007797 0.93 SMN1; SMN2 (0.51) POLBNPSR1KDM4EMAPTRXFP1
SCHEMBL3018595 0.92 THRB (0.51) POLBNPSR1KDM4EMAPTRXFP1
SCHEMBL3016473 0.91 CNR1 (0.43) POLBKDM4EMAPTSMN1; SMN2ALDH1A1
SCHEMBL3015670 0.91 SMN1; SMN2 (0.46) POLBSMN1; SMN2ALDH1A1L3MBTL1HSD11B1
SCHEMBL3009148 0.90 THRB (0.47) POLBMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3011971 0.90 ALDH1A1 (0.58) KDM4EMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3005450 0.90 SMN1; SMN2 (0.45) KDM4EMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3017572 0.90 SMN1; SMN2 (0.45) KDM4EMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3010733 0.90 ALDH1A1 (0.48) POLBNPSR1KDM4EMAPTRXFP1
SCHEMBL3006852 0.90 ALDH1A1 (0.48) POLBNPSR1KDM4EMAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885NPSR1 764/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.